Buy Phenylpiracetam powder
Phenylpiracetam is a nootropic molecule that was that was developed by modifying piracetam with a “phenyl” group, which in this case, makes the molecule have more stimulating properties. In was developed in 1983 and was used by Russian Cosmonauts to “increasing physical, mental and cognitive activities” in space. Buy Phenylpiracetam powder
A single dose of Phenylpiracetam powder has been shown to cause a “significant increase in locomotor activity” and a ‘significantly enhanced memory function in a passive avoidance response test” in mammals. Phenylpiracetam powder has shown to be effective in increasing physical endurance, adaptation and resistance to cold. Phenylpiracetam powder has been shown to improve cognition in persons with cognitive decline from organic causes. It has also been shown to improve cognition in youth with epilepsy. In animal trials Phenylpiracetam powder has been shown to improve retention latency by over 185%.
Side effect of Buy Phenylpiracetam powder
In 2003, the State Pharmacological Committee of Russia approved Phenylpiracetam powder for cerebrovascular deficiency, depression, apathy, attention and memory decline, and has been used in people who develop cognitive deficits and/or depression after encephalopathy and brain injuries. It was shown to increase quality of life in patients with encephalopathy after lesions, brain traumas and gliomas surgery. It resulted in improvements in anxiety and depression, which resulted in less discomfort and better ability to execute everyday activities.
In a comparative trial for asthenia and chronic fatigue syndrome (CFS), patients were treated with Phenylpiracetam powder (68 people), piracetam (65 people) and placebo (47 people). The scores of a ten-word memory test and attention switching tests for the phenylpiracetam improved relative to those of piracetam and placebo. Overall, 83% of asthenic and 87% of CFS patients responded well to Phenylpiracetam powder versus 48% and 55%, respectively, to piracetam. Buy Phenylpiracetam powder
Phenylpiracetam powder has exhibited an antiepileptic action in rodents. Its effective dose (300 mg/kg) decreased the metrazol (a drug used as a circulatory and respiratory stimulant)-induced seizure by 50%.
Phenylpiracetam powder was administered to patients in addition to one standard AED (including valproyl amide, carbamazepine, lamotrigine, topiramate or a barbiturate, or structured polytherapy with more than one of these drugs). It substantially mitigated the number and frequency of seizures of patients receiving AED only and the number of individuals with a desynchronous EEG profile decreased from eight to three, while the number of individuals with seizure remissions increased modestly.
Consistent with this, cognitive functions in epileptic patients based on an MMSE test improved to only a small extent.
Because the immune system has a crucial role in the pathogenesis of ischemia-stroke, titres of antibodies against the main myelin protein and phospholipids were measured in patients with acute cerebral stroke treated with Phenylpiracetam powder. The titres of both antibodies decreased, suggesting possible reduction of ongoing demyelination. In a two-arm parallel trial with patients receiving one tablet (80 people) and two tablets (40 people) a day, both MMSE and severity of stroke scores improved significantly, while only showing a trend toward improvement in daily living activities (Barthel test).